Urigen Pharmaceuticals, Inc. (Urigen) is a specialty pharmaceutical company engaged in the development and commercialization of therapeutic products for urological disorders. The Company’s product pipeline includes URG101, for the treatment of Painful Bladder Syndrome (PBS), which has completed a Phase II double blinded, placebo controlled, multi-center trial, and URG301, targeting urethritis and nocturia. Urigen specializes in the development of products for patients with urological ailments including, specifically, the development of products for amelioration Painful Bladder Syndrome/Interstitial Cystitis (PBS or PBS/IC), Urethritis, Nocturia and Overactive Bladder (OAB). Urology represents a specialty pharmaceutical market of approximately 12,000 physicians in North America. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of PBS.